Jay A Brieler1, Patrick J Lustman2, Jeffrey F Scherrer3, Joanne Salas3, F David Schneider3. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO, brielerj@slu.edu. 2. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO and The Bell Street Clinic, VA St. Louis Health Care System - John Cochran Division, St. Louis, MO, USA. 3. Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO.
Abstract
OBJECTIVE: Depression is prevalent in diabetes and is associated with increased risks of hyperglycaemia, morbidity and mortality. The effect of antidepressant medication (ADM) on glycaemic control is uncertain owing to a paucity of relevant data. We sought to determine whether the use of ADM is associated with glycaemic control in depressed patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A retrospective cohort study (n = 1399) was conducted using electronic medical record registry data of ambulatory primary care visits from 2008 to 2013. Depression and type 2 diabetes were identified from ICD-9-CM codes; ADM use was determined from prescription orders; and glycaemic control was determined from measures of glycated haemoglobin (A1c). Good glycaemic control was defined as A1c < 7.0% (53 mmol/mol). Generalized estimating equations were used to determine the effect of depression and ADM use on glycaemic control. RESULTS: Good glycaemic control was achieved by 50.9% of depressed subjects receiving ADM versus 34.6% of depressed subjects without ADM. After adjusting for covariates, depressed patients receiving ADM were twice as likely as those not receiving ADM to achieve good glycaemic control (odds ratio = 1.95; 95% confidence interval: 1.02-3.71). CONCLUSIONS: In this retrospective cohort study of a large sample of primary care patients with type 2 diabetes, ADM use was associated with improved glycaemic control.
OBJECTIVE:Depression is prevalent in diabetes and is associated with increased risks of hyperglycaemia, morbidity and mortality. The effect of antidepressant medication (ADM) on glycaemic control is uncertain owing to a paucity of relevant data. We sought to determine whether the use of ADM is associated with glycaemic control in depressedpatients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A retrospective cohort study (n = 1399) was conducted using electronic medical record registry data of ambulatory primary care visits from 2008 to 2013. Depression and type 2 diabetes were identified from ICD-9-CM codes; ADM use was determined from prescription orders; and glycaemic control was determined from measures of glycated haemoglobin (A1c). Good glycaemic control was defined as A1c < 7.0% (53 mmol/mol). Generalized estimating equations were used to determine the effect of depression and ADM use on glycaemic control. RESULTS: Good glycaemic control was achieved by 50.9% of depressed subjects receiving ADM versus 34.6% of depressed subjects without ADM. After adjusting for covariates, depressedpatients receiving ADM were twice as likely as those not receiving ADM to achieve good glycaemic control (odds ratio = 1.95; 95% confidence interval: 1.02-3.71). CONCLUSIONS: In this retrospective cohort study of a large sample of primary care patients with type 2 diabetes, ADM use was associated with improved glycaemic control.
Authors: Shan Xing; Gregory S Calip; Alex D Leow; Shiyun Kim; Glen T Schumock; Daniel R Touchette; Todd A Lee Journal: J Diabetes Complications Date: 2017-12-27 Impact factor: 2.852
Authors: Marta Lopez-Herranz; Rodrigo Jiménez-García; Zichen Ji; Javier de Miguel-Diez; David Carabantes-Alarcon; Clara Maestre-Miquel; José J Zamorano-León; Ana López-de-Andrés Journal: Int J Environ Res Public Health Date: 2021-06-04 Impact factor: 3.390